(Q36577478)

15 August 2017

The management of Sjögren's syndrome (English)

1 reference

15 August 2017

Haralampos Moutsopoulos

series ordinal

3

object named as

Haralampos M Moutsopoulos

1 reference

15 August 2017

2

Niki M Moutsopoulos

1 reference

15 August 2017

Clio P Mavragani

1

1 reference

PubMed ID

16932698

15 August 2017

language of work or name

1 reference

1 May 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

5

1 reference

15 August 2017

252-261

1 reference

https://scigraph.springernature.com/pub.10.1038/ncprheum0165

15 August 2017

0 references

cites work

Clinical manifestations and early diagnosis of Sjögren syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Sjögren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Recent advances in the management of ocular complications of Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

An update of the etiology and management of xerostomia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Oral sequelae of head and neck radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Oral candidal infections and antimycotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Effects of homeopathic treatment on salivary flow rate and subjective symptoms in patients with oral dryness: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Therapy of Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Evaluation and management of laryngopharyngeal reflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Central nervous system involvement in Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Response of vasculitic peripheral neuropathy to intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

2-chloro-2'-deoxyadenosine in the treatment of Sjögren's syndrome-associated B cell lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2'-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Induction of oral tolerance in experimental Sjogren's syndrome autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

Parotid sialography for diagnosing Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Dental and periodontal status of Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Esophageal function and Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0165

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0165

1 reference

PubMed ID

16932698

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16932698